Half-Million Children Could Die If U.S. AIDS Relief Is Dropped

Follow Drugslib on

Medically reviewed by Drugs.com.

By Dennis Thompson HealthDay Reporter

FRIDAY, April 11, 2025 — Nearly a half-million children could die from AIDS by 2030 if President Donald Trump follows through on plans to cut U.S. relief programs, a new study says.

As many as 1 million additional children will become infected with HIV and nearly 500,000 will die from AIDS by the end of the decade if the US President’s Emergency Plan for AIDS Relief (PEPFAR) is suspended or only receives limited, short-term funding, researchers project in The Lancet.

On top of that, as many as 2.8 million children could be left orphaned by AIDS deaths among adults, researchers said.

“Losing stable, long-term support for PEPFAR programs sets global progress to end HIV/AIDS back to the dark ages of the epidemic, especially for children and adolescents,” said co-lead researcher Lucie Cluver, a professor of child and family social work at the University of Oxford in the U.K.

“A sudden withdrawal of PEPFAR programs, especially in the absence of a long term strategy to replace them, could lead to a resurgence of HIV infections and preventable deaths, and a dramatic rise in the number of children orphaned by AIDS in the coming years – a setback that could erode two decades of progress,” she added in a news release.

The Trump Administration paused all foreign aid funding on Jan. 20, ostensibly for a 90-day review and evaluation, with only limited exceptions. Many of PEPFAR’s services have been disrupted or suspended since then, researchers noted.

Authorization for PEPFAR lapsed in late March, and the world is now watching and waiting to see what will come next.

PEPFAR was established in 2003 under President George W. Bush, and the program has become a cornerstone in addressing the global HIV/AIDS epidemic, researchers said in background notes.

PEPFAR is estimated to have saved more than 26 million lives and ensured that 7.8 million babies were born HIV-free, researchers said. The program currently supports more than 20 million people with HIV prevention and treatment services, mainly in sub-Saharan Africa.

For the new study, researchers projected what might happen in the absence of PEPFAR programs, based on current trends.

For example, prior to PEPFAR making antiretroviral HIV medications available in Africa, more than 20 million people in the region died from AIDS, leaving behind millions of orphaned children, researchers noted.

Under PEPFAR, the number of AIDS orphans in Africa has declined from 14 million children in 2010 to 10.5 million in 2023, researchers said.

PEPFAR also provides programs that prevent sexual violence and support child health and well-being, researchers added.

“Many of the children and adolescents who currently benefit from PEPFAR programs will slip through the cracks — increasing their chances of acquiring HIV or leading to further transmission, ultimately resulting in many preventable HIV infections and deaths,” co-researcher Susan Hillis, a senior research officer at Imperial College London, said in a news release.

Based on their projections, the researchers recommend a strategic, five-year transition plan under which African nations and charitable organizations will shoulder more of PEPFAR’s burden.

Countries in Africa have already increased their funding for HIV/AIDS response, going from $13 billion in 2004 to nearly $41 billion in 2021, researchers noted.

“What is urgently needed now is a well-planned transition to expanded country-ownership of PEPFAR programs that will take this lifesaving work forward and offer stability and sustainability for countries that currently rely on PEPFAR support now and into the future, which in turn also benefits the USA and solidifies its position as a global leader in the effort to end HIV,” researcher Chris Desmond of the University of Kwazulu-Natal in South Africa said in a news release.

Sources

  • The Lancet, news release, April 8, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-04-12 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords